Sarepta Therapeutics (SRPT)

$21.46 +0.32 (1.51%)
Market Cap 2.22B
Revenue (ttm) 1.90B
Net Income (ttm) 235.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 8.79
Profit Margin 12.37%
Debt to Equity Ratio 0.78
Volume 3,161,900
Avg Vol 4,290,542
Day's Range N/A - N/A
Shares Out 104.79M
Stochastic %K 32%
Beta 0.48
Analysts Sell
Price Target $19.86

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 4:13 AM
Enter: $SRPT Calls Strike Price: $22 Expiry Date: FEB 06 2026 Buy in Price: $1.38 - $2.15 Sell Price: $2.58 Profit : +87% (Turn every $1 into $1.87) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
DragonAlgo
DragonAlgo Jan. 13 at 11:06 PM
🐉 $SRPT CALL — DragonAlgo® Signal Contract: SRPT CALL Expiry: 2026-01-16 | Strike: $30.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 🔗 https://dragonalgo.com
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Jan. 13 at 10:57 PM
$SRPT at least it didn't slide further down .. Now we wait again
0 · Reply
UgoGreg
UgoGreg Jan. 13 at 10:57 PM
$SRPT https://youtu.be/m61diFB2Pag
0 · Reply
Thaigrlsrk
Thaigrlsrk Jan. 13 at 9:49 PM
$SRPT Bottom line this is a company with 4 approved therapies producing increasing revenues with the floor at 1.8B. Enough cash and revenues to bring positive cash flow while moving the best RNA platform of 7-11 new drugs each with Multibillion dollar potential. Safety risk for the drug is/has been addressed and the market will see that. Lots of possible big news this year from a firmly financed progressing drug company.
3 · Reply
7990E
7990E Jan. 13 at 9:27 PM
$SRPT There is no way this suckers are keeping this stock down at a cost Shorts are just selling to each other the same shares to keep the stock down with no risk and from now and then a buyer comes and the price goes up very fast once buyer is done buying they bring the price down again with no risk with the same selling to each other. But nothing last forever either they win or longs will that’s the game
0 · Reply
jm0olah
jm0olah Jan. 13 at 9:17 PM
Never ask a man his salary, a woman her age or Wall Street if $SRPT should trade for more than $24
0 · Reply
free2dream
free2dream Jan. 13 at 9:12 PM
$MRNA upgrades will follow. I posted many times here that this is being accumulated. $SRPT is exactly in the same setup, watch it gor from $20 to $200. Market is blind as a bat, buing the nose bleed in AI and $SOX , completely ignoring the $XBI $LABU sector and the beat up value names.
0 · Reply
tradeitbetit
tradeitbetit Jan. 13 at 8:55 PM
$BMRN gets upgraded - goes down Gets good news - goes down Announces 5x better results for DMD patients than $SRPT theraphy - goes down Wtf
0 · Reply
Holdem_Foldem
Holdem_Foldem Jan. 13 at 8:47 PM
$SRPT easy 2x from here $SPY
0 · Reply
Latest News on SRPT
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:36 PM EST - 1 day ago

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 11:58 AM EST - 1 day ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 12, 2026, 9:30 AM EST - 1 day ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 7, 2026, 8:30 AM EST - 6 days ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 8 days ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2025, 5:20 PM EST - 13 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Dec 17, 2025, 6:48 AM EST - 27 days ago

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Dec 11, 2025, 7:00 AM EST - 4 weeks ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 12:07 PM EST - 7 weeks ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 25, 2025, 8:57 AM EST - 7 weeks ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 7 weeks ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 24, 2025, 7:30 AM EST - 7 weeks ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 5:48 PM EST - 2 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:54 PM EST - 2 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 14, 2025, 2:08 PM EST - 2 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 1:39 PM EST - 2 months ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:33 PM EST - 2 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 12:11 PM EST - 2 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 9:55 AM EST - 2 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 6:20 AM EST - 2 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:36 AM EST - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 4, 2025, 4:27 AM EST - 2 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 6:26 PM EST - 2 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 2 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Nov 3, 2025, 4:05 PM EST - 2 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 27, 2025, 4:05 PM EDT - 2 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Oct 23, 2025, 6:46 AM EDT - 2 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 10, 2025, 11:49 AM EDT - 3 months ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

What's Going On Sarepta Stock On Wednesday?

Oct 8, 2025, 11:19 AM EDT - 3 months ago

What's Going On Sarepta Stock On Wednesday?

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Oct 3, 2025, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Sep 5, 2025, 9:00 AM EDT - 4 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 4 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 25, 2025, 3:11 AM EDT - 5 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 23, 2025, 7:08 AM EDT - 5 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 12:12 PM EDT - 5 months ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 22, 2025, 9:50 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Aug 20, 2025, 3:30 PM EDT - 5 months ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

Aug 18, 2025, 12:01 PM EDT - 5 months ago

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 14, 2025, 12:14 PM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

Aug 13, 2025, 4:12 PM EDT - 5 months ago

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline

Aug 13, 2025, 8:33 AM EDT - 5 months ago

SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

Aug 11, 2025, 8:18 AM EDT - 5 months ago

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 4:13 AM
Enter: $SRPT Calls Strike Price: $22 Expiry Date: FEB 06 2026 Buy in Price: $1.38 - $2.15 Sell Price: $2.58 Profit : +87% (Turn every $1 into $1.87) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
DragonAlgo
DragonAlgo Jan. 13 at 11:06 PM
🐉 $SRPT CALL — DragonAlgo® Signal Contract: SRPT CALL Expiry: 2026-01-16 | Strike: $30.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 🔗 https://dragonalgo.com
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Jan. 13 at 10:57 PM
$SRPT at least it didn't slide further down .. Now we wait again
0 · Reply
UgoGreg
UgoGreg Jan. 13 at 10:57 PM
$SRPT https://youtu.be/m61diFB2Pag
0 · Reply
Thaigrlsrk
Thaigrlsrk Jan. 13 at 9:49 PM
$SRPT Bottom line this is a company with 4 approved therapies producing increasing revenues with the floor at 1.8B. Enough cash and revenues to bring positive cash flow while moving the best RNA platform of 7-11 new drugs each with Multibillion dollar potential. Safety risk for the drug is/has been addressed and the market will see that. Lots of possible big news this year from a firmly financed progressing drug company.
3 · Reply
7990E
7990E Jan. 13 at 9:27 PM
$SRPT There is no way this suckers are keeping this stock down at a cost Shorts are just selling to each other the same shares to keep the stock down with no risk and from now and then a buyer comes and the price goes up very fast once buyer is done buying they bring the price down again with no risk with the same selling to each other. But nothing last forever either they win or longs will that’s the game
0 · Reply
jm0olah
jm0olah Jan. 13 at 9:17 PM
Never ask a man his salary, a woman her age or Wall Street if $SRPT should trade for more than $24
0 · Reply
free2dream
free2dream Jan. 13 at 9:12 PM
$MRNA upgrades will follow. I posted many times here that this is being accumulated. $SRPT is exactly in the same setup, watch it gor from $20 to $200. Market is blind as a bat, buing the nose bleed in AI and $SOX , completely ignoring the $XBI $LABU sector and the beat up value names.
0 · Reply
tradeitbetit
tradeitbetit Jan. 13 at 8:55 PM
$BMRN gets upgraded - goes down Gets good news - goes down Announces 5x better results for DMD patients than $SRPT theraphy - goes down Wtf
0 · Reply
Holdem_Foldem
Holdem_Foldem Jan. 13 at 8:47 PM
$SRPT easy 2x from here $SPY
0 · Reply
Weight_Of_Empty
Weight_Of_Empty Jan. 13 at 8:04 PM
$SRPT
0 · Reply
fel0n_drumpf
fel0n_drumpf Jan. 13 at 7:18 PM
$SRPT great call Freddy boy…have you ever made a profit in your life or are they all made from MsPaint?
1 · Reply
ignoreo
ignoreo Jan. 13 at 6:53 PM
$SRPT how is anyone supposed to trust them again when they say patients dying from their drug is immaterial to their drug's safety profile? you people havent realized just how low sales are going to go -- to zero.
1 · Reply
ArbVinnie
ArbVinnie Jan. 13 at 6:49 PM
$SRPT https://www.biospace.com/business/after-mortality-marred-year-sarepta-looks-ahead-to-catalyst-rich-2026
0 · Reply
iCro93
iCro93 Jan. 13 at 5:37 PM
$SRPT MRNA at 12b. MC and almost same revenue over the year.. Sept: eps is 2,34 mRNA: eps is - 9 .. lol
1 · Reply
zanwenhuahao
zanwenhuahao Jan. 13 at 5:18 PM
$SRPT bought another 1k at 21.25
0 · Reply
rebecca_brenner
rebecca_brenner Jan. 13 at 4:46 PM
$SRPT Sarepta has stayed in the arena for years. In rare disease biotech, persistence matters as much as brilliance. Still watching, still hopeful.
0 · Reply
Martelxo92
Martelxo92 Jan. 13 at 4:33 PM
$SRPT 12/31 short interest is up another 300,000 to 20,456,000 Digging in deeper.
0 · Reply
Carlza
Carlza Jan. 13 at 4:15 PM
$SRPT Down days force the simple question: has the thesis broken, or did the crowd get emotional? For $SRPT, I’m still in the “emotion” camp, with eyes open to risks, always.
1 · Reply
Find_the_Cure
Find_the_Cure Jan. 13 at 3:36 PM
$SRPT bought another 375
0 · Reply
jm0olah
jm0olah Jan. 13 at 3:16 PM
$SRPT part of me was worried that the low volume manipulation was gonna stop yesterday. Good to know it’s still going 🙄
0 · Reply
BiodegradableBurger
BiodegradableBurger Jan. 13 at 3:06 PM
$SRPT OK it’s 10am. About time the daily collapse starts. I hope today is an exception.
1 · Reply